Niflam (Morniflumate)

Morniflumate, the active ingredient in Niflam, is a fenamate non‑steroidal anti‑inflammatory drug (NSAID) presented as a rectal formulation for rectal use. It is employed to alleviate pain and reduce inflammation in adult patients suffering from musculoskeletal disorders and related conditions.

GNH USA supplies Niflam as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU GMP standards and providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels. The company ensures consistent quality and on‑time delivery to meet the therapeutic needs of patients across multiple regions.

Morniflumate is indicated for the management of pain and inflammation within the musculoskeletal system and related conditions.

- Pain relief: provides effective reduction of acute or chronic pain associated with inflammatory musculoskeletal disorders. - Inflammation reduction: decreases local prostaglandin‑mediated swelling and erythema in joints, tendons and soft tissues. - Musculoskeletal disorders: improves functional mobility and comfort in conditions such as osteoarthritis, rheumatoid arthritis and soft‑tissue injuries.

Morniflumate may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: mild stomach pain, dyspepsia or nausea. - Diarrhea: loose stools occurring during treatment. - Headache: transient head pain without neurological signs. - Dizziness: light‑headed sensation, especially after the first dose.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding: severe stomach or intestinal lesions. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Renal impairment: reduced kidney function or acute renal failure.

Before initiating Morniflumate therapy, clinicians should evaluate patient risk factors and monitor relevant parameters. - Assess gastrointestinal risk: avoid in patients with active ulcers or a history of GI bleeding. - Monitor liver function: perform baseline and periodic hepatic enzyme tests. - Monitor renal function: check creatinine clearance in patients with kidney disease. - Avoid in known hypersensitivity: discontinue if allergic reaction to fenamates occurs. - Use caution in elderly: lower doses may be required due to increased susceptibility. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Morniflumate can interact with several medicines, altering efficacy or safety profiles.

Major Interactions (Avoid): - Warfarin: increased risk of bleeding. - Other NSAIDs: additive gastrointestinal toxicity. - Corticosteroids: heightened chance of ulceration and bleeding.

Moderate Interactions (Monitor Closely): - ACE inhibitors: possible reduction in antihypertensive effect. - Diuretics: risk of renal function decline. - SSRIs: potential for increased bleeding tendency.